Bioxytrans consultant publishes book on hyperbaric oxygen therapy for stroke and Alzheimer’s patients

27.06.2024 – 13:09

BXT-25 is intended to supply the brain with oxygen

BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical-stage biotechnology company developing drugs to treat stroke and Alzheimer’s disease, announced that Bioxtran’s Scientific Advisor Prof. Avraham Mayevsky’s book entitled Hyperbaric oxygen supply Mitochondrial activity and physiological brain functions was published by Springer-Verlag. It is available as an e-book or hardcover. The book is directly linked to the Hypoxia platform technology, which uses as its analysis method the MDX Viewer, an FDA-cleared device for measuring tissue oxygenation. The device measures the consumption of oxygen molecules in tissues at the cellular level. The output of the MDX Viewer is the Brain Metabolic Score (BMS), which is an essential part of the approval process for Bioxytran’s acellular oxygen carrier molecule (AOC) called BXT-25. Bioxytran plans to use BXT-25 in its clinical trials for patients with ischemic stroke and Alzheimer’s disease as a replacement for hyperbaric oxygen treatment (HBOT).

https://link.springer.com/book/10.1007/978-3-031-49681-3

The book provides a comprehensive overview of the effects of hyperbaric oxygen on brain functions, including mitochondrial activity. The MDX Viewer is an FDA-approved medical device that measures tissue metabolic value, and its results are cited multiple times throughout the book. The MDX Viewer results provided a solid foundation upon which he could further explain the relationship between oxygenation and brain function in relation to hyperbaric oxygen treatment. The book also discusses the effects of hyperbaric oxygen treatment on brain biochemical and physiological responses that can affect mitochondrial activity, which is essential for energy production. The evidence suggests that hyperbaric oxygen improves brain blood flow and tissue oxygenation, ultimately having a positive impact on brain function and performance.

About Bioxytran, Inc.

Bioxytran, Inc. is a clinical-stage biotechnology company developing a drug to treat early-stage stroke and Alzheimer’s disease by delivering oxygen using a molecule 5,000 times smaller than a red blood cell. For more information, visit www.bioxytraninc.com

Investor Relations
Michael Sheikh
509-991-0245
[email protected]

Forward-looking statements

This press release contains forward-looking statements within the meaning of federal law, including those relating to the performance of the technology described in this press release. These forward-looking statements generally can be identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from those anticipated in such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and the risk factors set forth from time to time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under the federal securities laws.